TAMU Biology Logo
Deborah Kuhn

Instructional Assistant Professor

Fax: 979-845-2891
Email:
dkuhn@tamu.edu

Office:

116C HELD

Joined the Department in 2023

  • B.S., 2001, The University of South Florida
  • Ph.D., 2004, The University of South Florida, Cancer Biology
  • Postdoctoral research: The University of North Carolina at Chapel Hill, Lineberger Cancer Center, The University of Texas, M.D. Anderson Cancer Center

BIOL 403 Medical Narratives

Medical Narratives is a writing-intensive course that focuses on medical narratives—stories about health, illness, and medicine. We’ll read narratives throughout the course from both patient and provider perspectives. Any BIOL or BIMS major is welcome to take the course, although students pursuing a health-related career may find it more helpful than those interested in research. BIOL 213 or CHEM 228; junior or senior classification or instructor approval.

Kuhn DJ and Dou QP. Direct inhibition of the Interleukin-2 receptor -mediated signaling pathway induces G1 arrest and apoptosis in human head-and-neck cancer. J Cell Biochem. 95:379-390, 2005

Kuhn DJ, Zeger EL, and Orlowski RZ. Drugs: Proteasome Inhibitors and Modulators of Heat Shock Protein Function. In: Update on Cancer Therapeutics, Eds. R. Schilsky P.M. Sondel, G. Giaccone. 1:91-116, 2006

Kuhn DJ, Chen Q, Voorhees PM, Stader JS, Shenk KD, Sun CM, Demo SD, Bennett MK, van Leeuwen FW, Chanan-Khan AA, and Orlowski, RZ. Potent activity of carfilzomib, a novel, irreversible inhibitor of the ubiquitin-proteasome pathway, against pre-clinical models of multiple myeloma. Blood 110:3281-3290, 2007

Kuhn DJ, Hunsucker SA, Chen Q, Voorhees PM, Orlowski M, and Orlowski RZ. Targeted inhibition of the immunoproteasome is a potent strategy against models of multiple myeloma that overcomes resistance to conventional drugs and non-specific proteasome inhibitors. Blood 113:4667-4676, 2009

Kuhn DJ, Bjorklund CC, Orlowski RZ. Second Generation Proteasome Inhibitors: Carfilzomib and Immunoproteasome-specific Inhibitors (IPSIs). Curr Cancer Drug Targets 11:285-295, 2011

Kuhn DJ, Berkova Z, Jones RJ, Woessner R, Bjorklund CB, Ma W, Davis RE, Lin P, Wang H, Madden T, Wei C, Baladandayuthapani V, Wang M, Thomas SK, Shah JJ, Weber DM, and Orlowski RZ. Targeting the Insulin-like Growth Factor-1 Receptor to Overcome Bortezomib Resistance in Pre-clinical Models of Multiple MyelomaBlood 120:3260-70, 2012

Wu Q and Kuhn DJSerum Heavy Light, Chain Immunoassays Compared To Traditional Serum Based Laboratory Testing For The Diagnosis and Screening Of Monoclonal Gammopathies. B 

Kuhn DJ, Wang P, Shu I, Xuan J, Cao Z, and Savoldo B. Comparison of Free Light Chain Assay with Protein Electrophoresis for Screening and Monitoring PTLD.  

Kuhn DJ, Burfoot M, Lohmann T, and Benavides R. Elevated Free Light Chains in the Cerebral Spinal Fluid Are Associated with Positive Oligoclonal Banding in Patient Samples Being Evaluated in Multiple Sclerosis. 7th International Symposium on Clinical Applications of Free Light Chain and Heavy Light Chain Analysis. Hematology Reports 7 (s1):Abstract I145, 2015